Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Orexigen halts Contrave development for U.S., but the firm will appeal the division's "unprecedented" trial request through FDA's dispute resolution process.
Advertisement

Related Content

Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity
Orexigen Resurrects Contrave With New Trial Agreement With FDA
Vivus Will Cut Population In Qnexa Resubmission
Senate Wants FDA Plan To Speed Obesity Drug Development
Zafgen Obtains $33 Million In Series C Funds To Advance Anti-Obesity Drug In Phase II
Cardio Safety: Does FDA Expect More From Obesity Than Diabetes Products?
Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
FDA Pressed At Meridia Committee Review To Finalize Obesity Drug Guidance

Topics

Advertisement
UsernamePublicRestriction

Register

PS072449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel